Physician profile
Hsiupei Chen
NPI 1134230956
$2,357.44
in general payments reported to CMS, 2019-2025
29 companies · $932 in 2025
The $932 reported for 2025 was more than what a typical Pain Medicine (Anesthesiology) provider received nationally (typical 2025 total: $458).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $641 · 2020: $137 · 2021: $18.40 · 2022: $24.11 · 2023: $553 · 2024: $52.13 · 2025: $932.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,436 · Travel and Lodging: $101.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,435.94 |
| Travel and Lodging | $101.31 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Nevro Corp. | $550.79 | 2019-2023 | Senza |
| Globus Medical, INC. | $364.91 | 2025 | Senza |
| Boston Scientific Corporation | $186.06 | 2021-2025 | Intracept, Wavewriter Alpha Prime 16 |
| Si-Bone, INC. | $119.60 | 2025 | |
| Forte Bio-Pharma LLC | $94.04 | 2019-2023 | Prolate, Nalocet |
| Abbott Laboratories | $91.72 | 2019-2023 | Proclaim |
| Spr Therapeutics, INC | $85.00 | 2023 | Sprint Pns System |
| Medtronic, INC. | $82.97 | 2023 | Intellis Adaptivestim |
| Collegium Pharmaceutical, INC. | $77.19 | 2020-2023 | Belbuca |
| Scilex Pharmaceuticals INC. | $69.92 | 2019-2023 | Ztlido |
| Amgen INC. | $58.84 | 2019-2020 | |
| Stryker Corporation | $53.87 | 2025 | Omnicurve, Mild Device Kit |
| Vertos Medical, INC. | $52.13 | 2024 | Mild Device Kit |
| Abbvie INC. | $51.07 | 2023-2025 | Qulipta |
| Vertex Pharmaceuticals Incorporated | $46.55 | 2025 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Averitas Pharma INC. | $44.10 | 2023 | Qutenza |
| Penumbra, INC. | $42.24 | 2025 | Penumbra System |
| Mdd US Operations, LLC | $39.26 | 2019-2020 | |
| Nalu Medical, INC. | $38.91 | 2025 | Nalu Neurostimulation System |
| West Therapeutics Development, LLC | $33.54 | 2019-2020 | |
| Pfizer INC. | $27.90 | 2019-2023 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $27.05 | 2019-2020 | |
| Mml US, INC. | $26.16 | 2025 | Reactiv8 |
| Sonex Health, INC. | $19.55 | 2025 | Sx-One Microknife |
| Virtus Pharmaceuticals LLC | $18.66 | 2025 | Levorphanol Tartrate |
| Tersera Therapeutics LLC | $15.34 | 2020 | |
| Sentynl Therapeutics, INC. | $14.36 | 2019 | |
| Biodelivery Sciences International, INC. | $13.52 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $12.19 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hsiupei Chen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.